Innovative Eyewear Inc
LUCY Nasdaq Ophthalmic Goods Financials FY2021βFY2025
What Innovative Eyewear Inc does
No business description yet.
- Legal name
- Innovative Eyewear Inc
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 25, 2026
- Accession Β· CIK
- 0001829126-26-002695
0001808377
Revenue and margins
Innovative Eyewear Inc had $2.7M of revenue in fiscal 2025, up 62.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$7.3M in fiscal 2025, β276.1% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Innovative Eyewear Inc returned β to shareholders in fiscal 2025. The diluted share count rose 166.8%.
Balance sheet
Cash, debt and the ratios that show how comfortably Innovative Eyewear Inc can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.1M | $3.6M | $4.3M | $2.6M | $6.5M |
| Current ratio | 1.0x | 7.1x | 9.0x | 12.5x | 9.0x |
| Quick ratio | 0.6x | 6.9x | 8.1x | 11.4x | 7.4x |
| Total assets | $0.8M | $4.7M | $6.2M | $9.8M | $10.1M |
| Total liabilities | $0.6M | $0.7M | $0.7M | $0.7M | $1.1M |
| Shareholders' equity | $0.2M | $4.0M | $5.6M | $9.1M | $9.1M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 5 / 8 | 4 / 8 | 4 / 8 |
| Accruals ratio | β246.3% | β89.1% | β16.4% | β12.8% | β3.2% |
| Altman Z'' | β | β | β | β | β |
5 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $0.7M | $0.7M | $1.2M | $1.6M | $2.7M |
| Gross profit | $0.1M | β$0.1M | β$0.1M | $0.2M | $0.6M |
| Research and development | $0.1M | $0.5M | $0.7M | $0.8M | $0.7M |
| Interest expense | $0.0M | $0.1M | $0.0M | β | β |
| Net income | β$3.2M | β$5.7M | β$6.7M | β$7.8M | β$7.6M |
| Diluted EPS | β | β$0.87 | β$10.87 | β$5.19 | β$1.90 |
| Diluted shares | β | 0.01B | 0.00B | 0.00B | 0.00B |
| Cash flow | |||||
| Cash from operations | β$1.2M | β$3.2M | β$5.8M | β$6.7M | β$7.3M |
| Capital expenditure | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M |
| Free cash flow | β$1.2M | β$3.3M | β$5.8M | β$6.8M | β$7.3M |
| Depreciation and amortization | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $1.3M | $1.5M | $0.9M | $0.8M | $0.7M |
| Balance sheet | |||||
| Cash and short-term investments | $0.1M | $3.6M | $4.3M | $2.6M | $6.5M |
| Current assets | $0.6M | $4.2M | $5.6M | $9.2M | $9.4M |
| Current liabilities | $0.6M | $0.6M | $0.6M | $0.7M | $1.0M |
| Inventory | $0.3M | $0.1M | $0.5M | $0.8M | $1.7M |
| Property and equipment, net | $0.0M | $0.1M | $0.2M | $0.1M | $0.1M |
| Intangible assets | $0.1M | $0.1M | $0.3M | $0.5M | $0.6M |
| Total assets | $0.8M | $4.7M | $6.2M | $9.8M | $10.1M |
| Total liabilities | $0.6M | $0.7M | $0.7M | $0.7M | $1.1M |
| Shareholders' equity | $0.2M | $4.0M | $5.6M | $9.1M | $9.1M |
| Margins | |||||
| Gross margin | 21.5% | β8.5% | β10.4% | 13.2% | 21.3% |
| Net margin | β469.7% | β861.1% | β578.2% | β474.6% | β285.2% |
| FCF margin | β178.8% | β507.1% | β507.1% | β415.7% | β276.1% |
| Returns | |||||
| Return on equity | β1,563.6% | β268.5% | β139.1% | β106.0% | β83.6% |
| Return on assets | β393.6% | β206.1% | β122.2% | β96.7% | β76.0% |
| Return on tangible equity | β2,699.3% | β146.2% | β126.4% | β89.9% | β89.2% |
| Growth | |||||
| Revenue growth | β | β4.5% | 74.7% | 42.0% | 62.7% |
| Share count change | β | β | β90.6% | 144.1% | 166.8% |
| Financial health | |||||
| Current ratio | 1.0x | 7.1x | 9.0x | 12.5x | 9.0x |
| Quick ratio | 0.6x | 6.9x | 8.1x | 11.4x | 7.4x |
| Capital allocation | |||||
| Capex / revenue | 3.0% | 18.4% | 6.8% | 3.8% | 2.7% |
| Stock comp / revenue | 193.3% | 223.4% | 81.3% | 47.3% | 27.7% |
| Quality scores | |||||
| Piotroski F-score | β | 3.0 | 5.0 | 4.0 | 4.0 |
| Accruals ratio | β246.3% | β89.1% | β16.4% | β12.8% | β3.2% |
Source: SEC EDGAR XBRL filings (CIK 0001808377). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.